Catalyst Event
Johnson & Johnson (JNJ) · Other
From Akros SCHK HK-Global Brain-Computer Interface Index (ASHGBCI)
4/27/2026, 12:00:00 AM
On April 27, 2026, the FDA granted Priority Review for IMAAVY (nipocalimab) for the treatment of warm autoimmune hemolytic anemia (wAIHA), a rare blood disorder.
Korean Translation
2026년 4월 27일, 희귀 혈액 질환인 온난 자가면역 용혈성 빈혈(wAIHA) 치료를 위한 IMAAVY(니포칼리맙)가 FDA로부터 우선 심사 대상으로 지정됨.
Related Recent Events
Sonova Holding AG (SOON) · Other
The Annual General Meeting of shareholders is scheduled for 2026-06-16.
6/16/2026, 12:00:00 AM
Alphabet Inc (GOOGL) · Other
Ex-dividend date (2026-06-08) for a quarterly cash dividend of $0.22 per share, representing a 5% increase from the prior dividend. The dividend was declared on April 27, 2026 and is payable on June 15, 2026. A 1-2% price impact is estimated as dividend increases are generally viewed positively by the market, scheduled.
6/8/2026, 12:00:00 AM
Medtronic PLC (MDT) · Earnings Release
Medtronic will report its financial results for the fourth quarter and full fiscal year 2026 on June 3, 2026, scheduled. High importance is estimated due to the significant market impact typically associated with annual earnings reports.
6/3/2026, 12:00:00 AM
Sonova Holding AG (SOON) · Earnings Release
Publication of the full-year results for the 2025/26 financial year is scheduled. High importance is assigned as annual results typically drive significant market volatility.
5/18/2026, 12:00:00 AM
Shanghai Fosun Pharmaceutical (Group) Co Ltd (2196) · Other
An earnings briefing for the 2025 fiscal year and Q1 2026 results is scheduled for May 14, 2026. This routine communication event is estimated to have a price impact of at least 1% scheduled.
5/14/2026, 12:00:00 AM
CeriBell Inc (CBLL) · Earnings Release
First quarter 2026 financial results are scheduled to be released after market close on May 11, 2026, scheduled; high importance as earnings releases typically result in price movements exceeding 10%.
5/11/2026, 12:00:00 AM